A team of researchers from the University of Missouri and Belgrade have successfully created a safe and effective method for testing gallstone radiation therapy for safety and effectiveness.
NSAIDs are harmful to the cardiovascular system and can cause irreversible damage to cells of the central nervous system. Gallstone radiation therapy is an option for certain types of cancer, such as soft palate and testicular cancer, when heavy doses of radiation are administered over an extended period of time, and for severe, chronic conditions such as kidney cancer and leukemia.
This new method is able to protect participants from developing long-term side effects, increase the rate of test-mates, reduce test-clinician turnover, and introduce no unwanted biophysical emissions from a doctor.
One of the key advantages of this new, safer and more effective technology is the practical phase III testing provided by a laboratory.
“The test quickly and reliably withstood standard human clinical trials, 76 participants, including six participants with gallbladder cancer and two with renal cell carcinoma; and performed in parallel with the clinical trials,” said Giorgi Tani, PhD, associate professor of structural biology, chemistry and biological physics in the Mizzou School of Engineering, from the University of Missouri’s Robert W. and Joseph C. Byrd Health System, and the University of Serbia and Karabegovina (SGLK) in Serbia.
Dr. Tani explains that gallstones are salt crystals. The tests performed in that phase III trial showed for the first time that gallstone radiation therapy was able to impact levels of a key molecular marker (protein C1) against residual renal cell cancer, which was high regardless of glomerular levels and body mass index. This was evident to the participants who had one or two positive results.
“When we compared this to our body C-terminal end-point for developing G-athromic catheterization and total GLI-1 expression it became evident to us that gallstone radiation is able to control these abnormal markers,” said Dr. Tani. Tani has patented the technology and handed it over to MSU.
Dr. Tani is optimistic that this method of testing and validation plans to be adopted widely, and hopes it will benefit patients to learn if gallstones carry markers that indicate poor health, which is indicated by low glomerular or Raynauskappa-N-methyltransferase (GLMT)/CREB binding, but not promising outcomes, with a terminal lesion, or enlarged liver nodule, being present linked to clinically significant GLMT expression.
Gallstone radiated radiation is a single exposure to ionizing radiation for five minutes upon irradiation of a glomerulus through a special irradiator. One can normally expect to improve cholesterol levels after this exca pellet injection. MSU researchers have defined the dose-limits indicated by their subsequent validation.
“Our goal for medical use, as a test because of its universal validity, was to provide a procedure that would be both effective and pleasant to patients,” noted Dr. Tani.
He believes that the finding could be an important component in personalizing radiation therapies for gallstone cancer. Emerging radiotracer biomarkers that can identify patients who have not yet developed high levels of active tumor cells, as well as a predictor of body mass index within a post surgical context provide new and more efficient screening for patients with gallstone cancer, and reduced survival attempts.
“The applications of this technology include the prevention of early manifestations of glomerulonephritis, as well as reversal or treatment of patients who have failed standard radiation therapy and are at risk of recurrence,” he said.